Table 9 Results of meta-analysis.
From: Systematic review with meta-analysis: cytokines in fibromyalgia syndrome
Study | FMS | Controls | Weight | SMD | ||||
|---|---|---|---|---|---|---|---|---|
Mean | Std | Total | Mean | Std | Total | IV, Random, 95% CI | ||
IL-1: plasma, ELISA or immunoassay | ||||||||
Togo 2009 | 0.79 | 0.64 | 7 | 1.24 | 1.17 | 9 | 16.4% | -0.43 [-1.44, 0.57] |
Feng 2009 | 74.5 | 116.5 | 100 | 45.6 | 53.1 | 35 | 41.3% | 0.28 [-0.11, 0.66] |
Bazzichi 2007 | 4.54 | 9.7 | 80 | 7.44 | 6.62 | 45 | 42.3% | -0.33 [-0.70, 0.04] |
Total (95% CI) | 187 | 89 | 100.0% | -0.10 [-0.58, 0.39] | ||||
Heterogeneity: Tau2 = 0.11; Chi2 = 5.52, df = 2 (P = 0.06); I2 = 64% | ||||||||
Test for overall effect: Z = 0.39 (P = 0.69) | ||||||||
IL-6: plasma, ELISA or immunoassay or bioplex assay | ||||||||
Togo 2009 | 14.0 | 10.9 | 7 | 16.8 | 15.3 | 9 | 9.6% | -0.19 [-1.19, 0.80] |
Schwarz 2002 | 1.01 | 0.47 | 17 | 1.45 | 2.17 | 17 | 20.7% | -0.27 [-0.95, 0.40] |
Bazzichi 2007 | 2.76 | 3.99 | 80 | 4.34 | 4.51 | 45 | 69.7% | -0.38 [-0.74, -0.01] |
Total (95% CI) | 104 | 71 | 100.0% | -0.34 [-0.64, -0.03] | ||||
Heterogeneity: Tau2 = 0.00; Chi2 = 0.15, df = 2 (P = 0.93); I2 = 0% | ||||||||
Test for overall effect: Z = 2.15 (P = 0.03) | ||||||||
IL-6: serum, ELISA or immunoassay or bioplex assay | ||||||||
Gür 2002 | 5.52 | 3.96 | 81 | 5.46 | 1.37 | 32 | 25.7% | 0.02 [-0.39, 0.43] |
Hernandez 2010 | 16.28 | 8.13 | 64 | 0.92 | 0.32 | 25 | 24.8% | 2.20 [1.63, 2.77] |
Wallace 2001 | 7.19 | 2.02 | 56 | 6.3 | 6.72 | 36 | 25.6% | 0.20 [-0.22, 0.62] |
Wang 2008 | 2.57 | 1.38 | 20 | 0.92 | 0.32 | 25 | 23.9% | 1.71 [1.02, 2.40] |
Total (95% CI) | 221 | 118 | 100.0% | 1.01 [-0.03, 2.05] | ||||
Heterogeneity: Tau2 = 1.05; Chi2 = 51.09, df = 3 (P < 0.00001); I2 = 94% | ||||||||
Test for overall effect: Z = 1.91 (P = 0.06) | ||||||||
IL-8: plasma, ELISA or immunoassay | ||||||||
Bazzichi 2007 | 61.89 | 149.0 | 80 | 7.9 | 17.5 | 45 | 41.2% | 0.45 [0.08, 0.82] |
Blanco 2010 | 83.0 | 253.0 | 79 | 84.0 | 253.0 | 59 | 42.8% | -0.00 [-0.34, 0.33] |
Togo 2009 | 8.4 | 1.9 | 7 | 11.8 | 5.4 | 9 | 16.0% | -0.75 [-1.79, 0.28] |
Total (95% CI) | 166 | 113 | 100.0% | 0.06 [-0.43, 0.56] | ||||
Heterogeneity: Tau2 = 0.12; Chi2 = 6.23, df = 2 (P = 0.04); I2 = 68% | ||||||||
Test for overall effect: Z = 0.25 (P = 0.80) | ||||||||
TNF: serum, ELISA or immunoassay or bioplex assay | ||||||||
Hernandez 2010 | 20.42 | 7.24 | 64 | 35.73 | 0.72 | 25 | 33.0% | -2.46 [-3.05, -1.87] |
Wang 2008 | 3.27 | 5.08 | 20 | 3.89 | 12.95 | 80 | 33.5% | -0.05 [-0.54, 0.44] |
Üçeyler 2006 | 7.41 | 11.01 | 26 | 6.7 | 9.5 | 40 | 33.5% | 0.07 [-0.42, 0.56] |
Total (95% CI) | 110 | 145 | 100.0% | -0.81 [-2.31, 0.70] | ||||
Heterogeneity: Tau2 = 1.70; Chi2 = 49.74, df = 2 (P < 0.00001); I2 = 96% | ||||||||
Test for overall effect: Z = 1.05 (P = 0.29) | ||||||||
TNF: plasma, ELISA or immunoassay | ||||||||
Bazzichi 2007 | 22.59 | 29.55 | 80 | 11.07 | 6.77 | 45 | 28.0% | 0.48 [0.11, 0.85] |
Blanco 2010 | 163.0 | 435.0 | 79 | 161.0 | 319.0 | 59 | 28.5% | 0.01 [-0.33, 0.34] |
Feng 2009 | 12.2 | 10.2 | 100 | 40.1 | 73.5 | 35 | 27.6% | -0.73 [-1.12, -0.33] |
Togo 2009 | 0.24 | 0.13 | 7 | 0.7 | 0.61 | 9 | 16.0% | -0.93 [-1.98, 0.13] |
Total (95% CI) | 266 | 148 | 100.0% | -0.21 [-0.82, 0.39] | ||||
Heterogeneity: Tau2 = 0.30; Chi2 = 21.71, df = 3 (P < 0.0001); I2 = 86% | ||||||||
Test for overall effect: Z = 0.69 (P = 0.49) | ||||||||